Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $2,148,371.59 in Stock

Key Points

• Takeda insider Andrew Plump sold 116,191 shares for approximately $2.15 million at an average price of $18.49, reducing his direct ownership by 44.41%. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Takeda shares opened at $18.71 and are near their 52-week high of $18.90, while the company recently reported quarterly EPS of $0.95 and revenue of $7.50 billion—both above analyst expectations.
• Analyst sentiment remains mixed but leans positive, with one Strong Buy, two Buy, and one Sell rating producing a consensus “Moderate Buy” recommendation.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Andrew Plump sold 116,191 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the transaction, the insider directly owned 145,465 shares of the company's stock, valued at $2,689,647.85. The trade was a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Plump sold 19,651 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $18.49, for a total value of $363,346.99.
• On Monday, August 10th, Andrew Plump sold 165,393 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30.

Takeda Pharmaceutical Trading Up 1.5%

NYSE:TAK opened at $18.71 on Friday. The stock has a fifty day simple moving average of $17.26 and a 200 day simple moving average of $17.20. The firm has a market capitalization of $59.95 billion, a price-to-earnings ratio of 55.03 and a beta of -0.07. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $7.50 billion for the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TAK. Parkside Financial Bank & Trust lifted its holdings in Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company's stock worth $40,000 after purchasing an additional 1,684 shares during the last quarter. SHP Wealth Management acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $42,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company's stock worth $48,000 after acquiring an additional 2,328 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock worth $55,000 after purchasing an additional 1,292 shares during the period. Finally, Harbour Investments Inc. raised its position in shares of Takeda Pharmaceutical by 300.3% during the fourth quarter. Harbour Investments Inc. now owns 4,612 shares of the company's stock valued at $72,000 after buying an additional 3,460 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TAK. Weiss Ratings lowered Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, July 30th. Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of "Moderate Buy".

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source